CA3196989A1 - Pharmaceutical composition of glp-1/glp-2 dual agonists - Google Patents
Pharmaceutical composition of glp-1/glp-2 dual agonistsInfo
- Publication number
- CA3196989A1 CA3196989A1 CA3196989A CA3196989A CA3196989A1 CA 3196989 A1 CA3196989 A1 CA 3196989A1 CA 3196989 A CA3196989 A CA 3196989A CA 3196989 A CA3196989 A CA 3196989A CA 3196989 A1 CA3196989 A1 CA 3196989A1
- Authority
- CA
- Canada
- Prior art keywords
- glp
- composition
- concentration
- aspects
- dual agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20214558.7 | 2020-12-16 | ||
| EP20214558 | 2020-12-16 | ||
| PCT/EP2021/086148 WO2022129312A1 (en) | 2020-12-16 | 2021-12-16 | Pharmaceutical composition of glp-1/glp-2 dual agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196989A1 true CA3196989A1 (en) | 2022-06-23 |
Family
ID=74141273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196989A Pending CA3196989A1 (en) | 2020-12-16 | 2021-12-16 | Pharmaceutical composition of glp-1/glp-2 dual agonists |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230405088A1 (https=) |
| EP (1) | EP4262746A1 (https=) |
| JP (1) | JP2023553563A (https=) |
| KR (1) | KR20230121824A (https=) |
| CN (1) | CN116723850A (https=) |
| AU (1) | AU2021401137B2 (https=) |
| CA (1) | CA3196989A1 (https=) |
| CL (1) | CL2023001745A1 (https=) |
| IL (1) | IL301891A (https=) |
| MX (1) | MX2023006280A (https=) |
| TW (1) | TW202241491A (https=) |
| WO (1) | WO2022129312A1 (https=) |
| ZA (1) | ZA202304233B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| IL301892A (en) * | 2020-12-16 | 2023-06-01 | Zealand Pharma As | Drug composition of dual GLP-1/GLP-2 agonists |
| JP2024533153A (ja) * | 2021-09-03 | 2024-09-12 | ジーランド ファーマ エー／エス | 投薬レジーム |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| UA95235C2 (en) * | 2005-05-04 | 2011-07-25 | Зииланд Фарма А/С | Glucagon-like-peptide-2 (glp-2) analogues |
| IN2015DN00544A (https=) * | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| KR20200080331A (ko) * | 2012-07-23 | 2020-07-06 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| JP6822839B2 (ja) * | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
| KR102455171B1 (ko) * | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| EP3551651B1 (en) * | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
-
2021
- 2021-12-16 MX MX2023006280A patent/MX2023006280A/es unknown
- 2021-12-16 JP JP2023536097A patent/JP2023553563A/ja active Pending
- 2021-12-16 EP EP21836186.3A patent/EP4262746A1/en active Pending
- 2021-12-16 IL IL301891A patent/IL301891A/en unknown
- 2021-12-16 KR KR1020237023829A patent/KR20230121824A/ko active Pending
- 2021-12-16 US US18/037,795 patent/US20230405088A1/en active Pending
- 2021-12-16 CN CN202180079922.4A patent/CN116723850A/zh active Pending
- 2021-12-16 WO PCT/EP2021/086148 patent/WO2022129312A1/en not_active Ceased
- 2021-12-16 CA CA3196989A patent/CA3196989A1/en active Pending
- 2021-12-16 AU AU2021401137A patent/AU2021401137B2/en active Active
- 2021-12-16 TW TW110147095A patent/TW202241491A/zh unknown
-
2023
- 2023-04-06 ZA ZA2023/04233A patent/ZA202304233B/en unknown
- 2023-06-14 CL CL2023001745A patent/CL2023001745A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022129312A1 (en) | 2022-06-23 |
| US20230405088A1 (en) | 2023-12-21 |
| KR20230121824A (ko) | 2023-08-21 |
| CN116723850A (zh) | 2023-09-08 |
| AU2021401137B2 (en) | 2024-09-05 |
| CL2023001745A1 (es) | 2024-01-19 |
| TW202241491A (zh) | 2022-11-01 |
| ZA202304233B (en) | 2025-08-27 |
| IL301891A (en) | 2023-06-01 |
| AU2021401137A1 (en) | 2023-06-08 |
| MX2023006280A (es) | 2023-06-13 |
| JP2023553563A (ja) | 2023-12-22 |
| EP4262746A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12576025B2 (en) | Pharmaceutical parenteral composition of dual GLP1/2 agonist | |
| AU2021401137B2 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| AU2021399904B2 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| EP4262745B1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| RU2855486C1 (ru) | Фармацевтическая композиция двойных агонистов glp-1/glp-2 | |
| RU2852511C1 (ru) | Фармацевтическая композиция двойных агонистов glp-1/glp-2 | |
| RU2855506C1 (ru) | Фармацевтическая композиция двойных агонистов glp-1/glp-2 | |
| TWI921427B (zh) | Glp-1/glp-2雙重促效劑之醫藥組合物 | |
| HK40095698A (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| HK40095698B (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241212 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241212 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250225 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251118 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251118 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251119 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260127 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260127 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260128 |